Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
9
×
national blog main
texas blog main
9
×
texas top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
cancer
eli lilly
ipo
novartis
crispr
drugs
medical devices
teva pharmaceutical
venture capital
amgen
asklepios biopharmaceutical
What
new
9
×
bio
fda
roundup
drug
ipo
million
approval
cancer
class
companies
crispr
developing
drugs
group
isn’t
life
medicines
migraine
science
therapeutics
won
activity
added
adds
allogene
amgen
antonio
approvals
approved
arguments
babies
bails
big
biogen
biopharma
biotechs
brand
bridgebio
candidates
Language
unset
Current search:
new
×
fda
×
" texas blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
San Antonio Startup Making Noise-Reducing Tech for Babies Adds $1.3M
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines